Article Sidebar

PDF
Date Published: 02/06/2021
Abstract Views: 584
Views PDF: 175
DOI: https://doi.org/10.51298/vmj.v499i1-2.231
Issue
Vol. 499 No. 1-2 (2021)
Section
Các bài báo
How to Cite
Hoàng Phương Khanh, P., Đặng Anh Thư, P., & Hữu Công, N. (2021). ANTI-SRP MYOPATHY - THE FIRST CASES IN VIETNAM. Vietnam Medical Journal, 499(1-2). https://doi.org/10.51298/vmj.v499i1-2.231

ANTI-SRP MYOPATHY - THE FIRST CASES IN VIETNAM

Phan Hoàng Phương Khanh, Phan Đặng Anh Thư, Nguyễn Hữu Công

Main Article Content

Abstract

Anti-SRP myopathy is the subtype of immune mediated necrotizing myopathy which is associated with anti-signal recognition particle (SRP) antibody. This disease has never been mentioned in the medical reports in Vietnam. In this paper, the clinical, laboratory and therapeutic characteristics of three cases with anti-SRP myopathy are described. All the cases had typical clinical features and serum positive for anti-SRP antibody. Two cases had appropriate histopathological changes and the other had atypical changes. One patient responded well to Rituximab, one had a limited response to two combined immunosuppressants, and the third did not respond to rituximab and had poor tolerance to immunosuppressants. The important role of antibody testing for diagnosis and the problems with treatment for this very newly known anti-SRP myopathy in Vietnam should be emphasized.

Article Details

Author Biography

Nguyễn Hữu Công,

Anti-SRP myopathy is the subtype of immune mediated necrotizing myopathy which is associated with anti-signal recognition particle (SRP) antibody. This disease has never been mentioned in the medical reports in Vietnam. In this paper, the clinical, laboratory and therapeutic characteristics of three cases with anti-SRP myopathy are described. All the cases had typical clinical features and serum positive for anti-SRP antibody. Two cases had appropriate histopathological changes and the other had atypical changes. One patient responded well to Rituximab, one had a limited response to two combined immunosuppressants, and the third did not respond to rituximab and had poor tolerance to immunosuppressants. The important role of antibody testing for diagnosis and the problems with treatment for this very newly known anti-SRP myopathy in Vietnam should be emphasized.

Keywords

anti-SRP myopathy, anti-signal recognition particle (SRP) antibody, immune mediated necrotizing myopathy

References

1. Pinal-Fernandez I, Mammen AL. Spectrum of immune-mediated necrotizing myopathies and their treatments. Curr Opin Rheumatol 2016; 28:619–24.
2. Suzuki S, Hayashi YK, Kuwana M, Tsuburaya R, Suzuki N, Nishino I. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol 2012; 69: 728–32.
3. Nakamura, T. Coexistence of Anti-SRP and Anti-SS-A/Ro Antibodies in Inflammatory Myopathy: Does the Association Occur by Chance? A Case Report. SN Compr. Clin. Med 2020; 2: 822–828.
4. Allenbach Y, Mammen A, Benveniste O, Stenzel W 224 th ENMC International Workshop: Clinico-sero-pathological classification of immune mediated necrotizing myopathies. Neuromuscular Disorders 2018; 28: 87-99.
5. Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayama K, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 2016; 87:1038–44.